On a late August day in an industrial corner of Baltimore that had been mostly silenced by the pandemic, a red-brick manufacturing plant was buzzing with activity. Deep in the building, in a zone called Area 3, the stainless steel shell of a bioreactor lay on its side, having just arrived from Massachusetts. Employees had begun the task of making the bioreactor operational. Within weeks it would be the center of a production line for coronavirus vaccines.


OWS deals have led to a huge payday for many pharma executives. Moderna executives netted a profit of $115.5 million from selling shares in their company from May 15 to Aug. 31, according to Accountable Pharma, a nonpartisan watchdog group.

back to top